Shaokun Wang, Yanxia Gao, Jie Ran, Yan Zhang, Yanling Chen, Hongyi Yan, Li Pang
{"title":"A Critical Four-Hour Therapeutic Window Predicts Delayed Encephalopathy Risk After Carbon Monoxide Poisoning: A Multicenter Retrospective Cohort Study.","authors":"Shaokun Wang, Yanxia Gao, Jie Ran, Yan Zhang, Yanling Chen, Hongyi Yan, Li Pang","doi":"10.1002/cns.70837","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The therapeutic window for preventing delayed encephalopathy after carbon monoxide poisoning (DEACMP) remains unclear. We aimed to define this temporal risk relationship and establish an intervention threshold using machine learning.</p><p><strong>Methods: </strong>In this multicenter retrospective cohort study (n = 1755), a gradient boosting model for predicting DEACMP was developed (n = 1654) and externally validated (n = 101). Performance was assessed using the area under the receiver operating characteristic curve (AUC) and interpreted using Shapley Additive exPlanations (SHAP).</p><p><strong>Results: </strong>The exposure-to-treatment interval was the most powerful predictor of DEACMP risk. Intervention within four hours emerged as the most critical variable influencing risk (SHAP analysis). The model demonstrated robust discrimination in the training (AUC = 0.944, 95% CI, 0.926-0.960), internal validation (AUC = 0.849, 95% CI, 0.785-0.905), and external validation (AUC = 0.872, 95% CI, 0.772-0.946) sets.</p><p><strong>Conclusion: </strong>Treatment delay is the primary modifiable risk factor for DEACMP following CO poisoning. The identified critical four-hour therapeutic window provides the first quantitative, evidence-based benchmark to inform clinical guidelines and optimize emergency response strategies aimed at preventing delayed neurological sequelae.</p>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"32 3","pages":"e70837"},"PeriodicalIF":5.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13093570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cns.70837","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: The therapeutic window for preventing delayed encephalopathy after carbon monoxide poisoning (DEACMP) remains unclear. We aimed to define this temporal risk relationship and establish an intervention threshold using machine learning.
Methods: In this multicenter retrospective cohort study (n = 1755), a gradient boosting model for predicting DEACMP was developed (n = 1654) and externally validated (n = 101). Performance was assessed using the area under the receiver operating characteristic curve (AUC) and interpreted using Shapley Additive exPlanations (SHAP).
Results: The exposure-to-treatment interval was the most powerful predictor of DEACMP risk. Intervention within four hours emerged as the most critical variable influencing risk (SHAP analysis). The model demonstrated robust discrimination in the training (AUC = 0.944, 95% CI, 0.926-0.960), internal validation (AUC = 0.849, 95% CI, 0.785-0.905), and external validation (AUC = 0.872, 95% CI, 0.772-0.946) sets.
Conclusion: Treatment delay is the primary modifiable risk factor for DEACMP following CO poisoning. The identified critical four-hour therapeutic window provides the first quantitative, evidence-based benchmark to inform clinical guidelines and optimize emergency response strategies aimed at preventing delayed neurological sequelae.
期刊介绍:
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.